Jay Venkatesan
CIK 1413350 · See Remarks · last filed 2026-09-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ANGN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
230 CALIFORNIA ST, SUITE 600
SAN FRANCISCO, CA 94111
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ELTX | Director | 180,534 | $1.44 | $260.0K | $0 | 7 | 2026-09-02 |
| SER | Director | 232,294 | $1.35 | $313.6K | $1.0K | 5 | 2026-06-22 |
| ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted | Director | 256,759 | $64.97 | $16.68M | -$2.74M | 11 | 2022-07-19 |
| Elicio Therapeutics, Inc. (ANGN) Delisted | See Remarks | 143,952 | $10.00 | $1.44M | -$3.95M | 10 | 2022-05-27 |
| XCUR | Director | 3,123 | $0.91 | $2.9K | $500.0K | 3 | 2020-07-08 |
| IOVANCE BIOTHERAPEUTICS, INC. (LBIO) Delisted | Director | — | — | — | $0 | 3 | 2017-06-05 |
| Cascadian Therapeutics, Inc. (ONTY) Delisted | EVP and General Manager | 4,076,723 | — | — | $500.0K | 7 | 2014-12-16 |
| Targanta Therapeutics Corp. (TARG) Delisted | Director | 2,092,987 | — | — | $5.75M | 2 | 2008-06-03 |
Recent Filings · Page 3 of 6
55 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-12-20 | Elicio Therapeutics, Inc. (ANGN) Delisted | Buy (P) | +41,625 | $106.0K | EDGAR |
| 2021-12-17 | Elicio Therapeutics, Inc. (ANGN) Delisted | Mixed | +36,513 | -$379.3K | EDGAR |
| 2021-09-21 | ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted | Sell (S) | −400,000 | -$3.76M | EDGAR |
| 2021-04-23 | ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted | Exer (M) | +15,300 | $59.0K | EDGAR |
| 2021-02-11 | Elicio Therapeutics, Inc. (ANGN) Delisted | Mixed | +211,365 | -$1.53M | EDGAR |
| 2021-02-08 | Elicio Therapeutics, Inc. (ANGN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-01-05 | ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-12-22 | ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted | Other (J) | −812,777 | $0 | EDGAR |
| 2020-07-08 | XCUR | Exer (M) | +22,240 | $19.4K | EDGAR |
| 2020-06-08 | XCUR | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.